Biotechs Recursion, Exscientia Merge For $850M And 10 Trials
The resultant biotech, which the businesses announced on Thursday, would have a pipeline that may produce 10 clinical readouts over the next 18 months, with a combined cash of $850 million. According to a statement made on Thursday, the AI-enabled biotechs Recursion and Exscientia have merged to form a business with $850 million in capital […]
Abzena Supplies Clinical Trial Material for Angiex’s Phase I Study of AGX101, a First-in-Class TM4SF1-directed ADC
Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for their Phase 1 clinical trial of AGX101, a first-in-class TM4SF1-directed Antibody-Drug Conjugate (ADC). Angiex partnered with Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, to support the development, manufacture and supply of clinical […]
IAEA Unveils New Database For Global Radiopharmaceuticals
Research, cooperation, and the sustainability of safe radiopharmaceuticals for clinical application will be aided by a new IAEA radiopharmacy database. To compile into the new online database, the IAEA is now gathering data on facilities that manufacture medical radioisotopes for use in radiopharmaceuticals globally, in addition to those that generate radiopharmaceuticals. The database seeks to […]
How Are ADCs Improving Cancer Treatments With Precision
ADCs could lead to better and more efficient treatments in the complex and specialized field of tailored cancer medicines. ADCs are made up of a monoclonal antibody that is permanently linked to a lethal drug. They were created as biological missiles with the goal of being very specific in their targets and having very strong […]
Antibody Drug Conjugates: Future Therapies And Treatment
Beyond cancer, there are a number of sectors that provide considerable prospects for antibody drug conjugates (ADCs), using their capacity to deliver therapeutic drugs selectively to sick cells or tissues while avoiding off-target effects. These opportunities may be used in a number of different fields. Several preclinical and clinical studies are now being conducted to […]
Advancements In ADCs: Important Trends And Market Insights
Antibody drug conjugates (ADCs) are the main players in the fields of cancer clinical research and deal-making, with new alliances and contracts appearing on a regular basis. Businesses set themselves apart as the ADC market grows increasingly saturated by concentrating on novel targets and linkers. ADCs have been at the forefront of high-value pharmaceutical acquisitions […]
BIO Asia-Taiwan 2024 concludes successfully
Number of visitors and business opportunities reach new highs Inaugural BIO Asia Awards presented, and expansion of conference into three tracks highlight Taiwan as important partner for biotech development in Asia With the final day of the four-day BIO Asia–Taiwan 2024 Exhibition concluding today, the BIO Asia-Taiwan 2024 series of events draws to a close. […]
Authenticx Announces AI Solution Revolutionizing Adverse Event Reporting
Authenticx, the new standard in healthcare for listening at scale, today announced a next-generation solution and suite of AI models that can detect healthcare-specific reportable events. The innovative models revolutionize contact center operations and empower pharmacovigilance and patient safety teams to operate more efficiently and with more context while significantly reducing risk. The new suite […]
At Pack Expo, MHI to Demo Small-batch Blister Machine for Stability Tests & Clinical Trials
Erie , CO – Maruho Hatsujyo Innovations (MHI) – the U.S. subsidiary of Maruho Hatsujyo Kogyo Co. Ltd, a Japanese company with subsidiaries in Asia and the U.S. will showcase a blister machine specifically intended for stability testing, clinical trials and similar small-run applications at Pack Expo Booth W-15058 , November 3-6 in Chicago. The […]
Eli Lilly Invests In Actinium-225 To Support Radiopharma
The largest pharmaceutical company in the world based on market value, Eli Lilly, is getting into the nuclear isotope manufacturing industry as cancer medicine manufacturers want to ensure a supply of radioactive elements essential to the developing area of radiopharmaceutical oncology therapies. The Indianapolis-based pharmaceutical company has made a $10 million convertible loan investment in […]
